Last reviewed · How we verify
Genolar® + Symbicort®
This combination product pairs a long-acting beta-2 agonist (formoterol) with an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.
This combination product pairs a long-acting beta-2 agonist (formoterol) with an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Genolar® + Symbicort® |
|---|---|
| Also known as | omalizumab & (budesonide+formoterol), GNR-044 & (budesonide+formoterol) |
| Sponsor | AO GENERIUM |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Beta-2 adrenergic receptor; glucocorticoid receptor |
| Modality | Biologic |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Genolar® contains formoterol, which activates beta-2 adrenergic receptors on airway smooth muscle to cause bronchodilation, while Symbicort® (budesonide/formoterol) provides both anti-inflammatory effects via glucocorticoid receptor activation and additional bronchodilation. The combination addresses both the inflammatory and obstructive components of chronic airway disease.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
Key clinical trials
- An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genolar® + Symbicort® CI brief — competitive landscape report
- Genolar® + Symbicort® updates RSS · CI watch RSS
- AO GENERIUM portfolio CI